TUDCA Information (On Cycle Support)


Manufactured by:

Serving Size: 1 Capsule
Servings per Container: 60

Active Ingredient
Tauroursodeoxycholic acid - 250mg

Other ingredients
Gelatin (capsule), Magnesium Stearate and Silica

Manufacturer recommended use: Take one capsule twice daily with food.

LiverLonger was a very popular TUDCA supplement, but with it's discontinuation, an opportunity has opened up for other companies to take advantage of.

TUDCA has been show in mayb studies to help prevent the specific type of damage 17-aa methylated steroids can cause. Recently, advanced users have begun to consider it the only worthwhile liver protectant.

If you're considering any 17-aa compound, TUDCA ought to be a must-have in your support supplement regimin.

Member Rating for TUDCA
only members can rate
Current Rating: 9.5


Gelatin is a tasteless substance created from collagen found in animal skin and bones. It is used to thicken liquid in processed foods as well as having applications in photography, cosmetics, and pharmaceuticals. Gelatin is found in many forms of candy, marshmallows, Jell-O, and some types of yogurt. Gelatin can be bought in many grocery stores for use in home cooking. In the vast majority of cases, gelatin is not harmful to the consumer.

Magnesium Stearate

Magnesium stearate is often used as a diluent in the manufacture of medical tablets, capsules and powders. In this regard, the substance is also useful, because it has lubricating properties, preventing ingredients from sticking to manufacturing equipment during the compression of chemical powders into solid tablets.

Magnesium stearate is the most commonly used lubricant for tablets. Studies have shown that magnesium stearate may affect the release time of the active ingredients in tablets, but not that it reduces the over-all bioavailability of those ingredients.

Silicon Dioxide (Silica)

The chemical compound silicon dioxide, also known as silica, is an oxide of silicon. Silica is most commonly found in nature as sand or quartz.

Silica is common additive in the production of foods, where it is used primarily as a flow agent in powdered foods, or to absorb water in hygroscopic applications. It is the primary component of diatomaceous earth which has many uses ranging from filtration to insect control. It is also the primary component of rice husk ash which is used, for example, in filtration and cement manufacturing.

Tauroursodeoxycholic Acid (TUDCA)

Tauroursodeoxycholic acid (TUDCA) is a liver aid introduced as a supplement by ThermoLife in their product Liver Longer. It looks like a good resource for preventing cholestasis, one of the major risks with 17 alkylated steroids.

Tauroursodeoxycholic acid is an anti-cholestatic agent, modulating protein kinase C (PKC) pathway. PKC reduces ischemic damage in several organs. Its isoform modulates ezrin, a key protein in the maintenance of cell lamellipoidal extensions.

TUDCA, a metabolite to UDCA (Ursodeoxycholic acid), is basically a particular Bile Acid enzyme that is naturally produced in the Liver. TUDCA has been proven in over 220 documented cases to dramatically improve both the performance of the liver as well as decrease pre-existing damage. TUDCA (Liver Longer) reduces the enzymatic stress on the liver. TUDCA/UDCA has been proven in double-blind study's to reduce enzymatic stress caused by methylation by an average of 41%.

A multicenter, cooperative study involving 12 hospitals throughout Italy evaluated the effects of long-term oral administration of TUDCA (500 mg/d for 3 months) on serum liver enzymes, total bilirubin, and serum lipid levels in patients with biopsy-proven chronic hepatitis due to hepatitis C virus (HCV) or hepatitis B virus (HBV) infection.

TUDCA was well tolerated and safe and was associated with a significant (P < 0.001) decrease in all serum liver enzyme levels. A slight improvement in total bilirubin levels was also observed. In addition, TUDCA caused a slight but significant improvement in serum lipid profiles.

These favorable changes were similar in HCV and HBV hepatitis and were independent of age, sex, body weight, and alcohol consumption. These results indicate TUDCA may have a place in the treatment of patients with chronic hepatitis, a possibility that needs to be verified by means of long-term, prospective, placebo-controlled, double-blind studies.